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Abstract Selenium is an essential element with remarkable
chemical properties. The similarity to sulphur results in a
number of chemical interactions mainly connected to thiols
and redox processes. The element modulates cell growth; in
low concentrations it is absolutely required for growth and
an essential component of serum free growth media.
However moderate to high concentrations potently inhibit
cell growth. The inhibitory effects are tumour specific and
selenium induces apoptosis in malignant cells at concen-
trations that do not affect the viability of normal cells.
Depending on concentration and chemical form selenium
may prevent or treat tumour disease. Selenium supplemen-
tation has been found to be of value in preventing
hepatocellular cancer by hepatitis B, in reducing the
incidence of liver cancer in general and in decreasing
mortality of colorectal, lung and prostate cancer. This
review focuses on the current knowledge of the preventive
effects of selenium with special emphasis on major human
tumours. The unique chemical properties along with
metabolism and preventive mechanisms are also discussed.
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Selenium—chemical properties
Selenium was discovered by Berzelius in 1818 [1]. Already
in the original publication the striking similarity to sulphur
and tellurium was described. However, there are a few
important differences between selenium and sulphur
explaining the major biological effects that are observed
in biomolecules where selenium is in place of sulphur.
The atomic radius of selenium (1.79Å) is slightly larger
and the electronegativity slightly lower than that of sulphur.
Both elements exist naturally in five different valence
states: −2, 0, +2, +4, and +6 and all sulphur compounds
have selenium analogues as exemplified in Table 1.
Selenium oxides are strong oxidising agents and selenium
compounds with selenium in the higher oxidation states are
less stable compared to the corresponding sulphur com-
pounds [2]. Selenols are relatively strong acids and the pKa
of the selenol in selenocysteine is 5.24 compared to 8.25 for
the thiol of cysteine [3]. Thus, at physiological pH the
selenol of selenocysteine exists in the anionic form whereas
the thiol in cysteine exists in the protonated form. This
property together with the larger atomic radius and higher
nucleophilicity of selenium can explain the differences in
the properties of proteins containing selenocysteine com-
pared to those with cysteine. However in selenomethionine
the relatively more reactive nucleophilic selenium is
blocked by a methyl group explaining why proteins
containing selenomethionine have similar properties com-
pared to methionine containing proteins.
The similarities together with the small differences
between selenium containing biomolecules and their sul-
phur counterparts explain the importance of selenium for
cell growth, proliferation and tumour prevention.
Selenium metabolism
The similarity to sulphur is also reflected in the metabolism
of selenium. Selenomethionine and selenocysteine are
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indiscriminately incorporated into proteins instead of
methionine and cysteine since the tRNAs cannot discrim-
inate the selenium from the sulphur form. The presence of
selenocysteine in place of cysteine may alter tertiary
structures of proteins and also the activity of redox proteins
if selenocysteine is incorporated at critical positions i.e.
active sites or regulatory units. Selenomethionine is
incorporated mainly in albumin, and thereby stored as an
inactive form, with the consequent delay of metabolism [4].
Supplementation with selenomethionine will thus lead to a
prolonged increase in total plasma selenium but a small or
no fraction of active selenium. Eventually selenomethionine
may be converted to selenocysteine by the transelenation
reaction [5] or undergo cleavage of the carbon-selenium
link by gamma lyase, the latter reaction however is believed
to be of minor importance in mammals [6]. Selenocysteine
is cleaved by beta-lyase to alanine and selenide [6].
The redox active naturally occurring selenium com-
pound selenite (SeO3
2−) will efficiently react with free or
protein bound thiols, at an exact stoichiometry, to form
selenium trisulfides [7]:
4 RSH þ H2SeO3 ! RSSRþ RS Se SRþ 3H2O
The appearance of selenium trisulfides may cross-link
proteins resulting in impaired protein function and this
mechanism may explain some pharmacological/toxic
effects of selenium [8]. Furthermore a number of chemical
modifications of the active sites of redox proteins may
markedly influence the activity and form the base for the
diverse biological effects of selenium (Fig. 1).
Selenodiglutathione (GS-Se-SG) is an extensively stud-
ied redox active selenotrisulfide. Selenite and GS-Se-SG
efficiently reacts with thiols. Reactions of these compounds
with GSH and glutathione reductase [9], the thioredoxin
system [10, 11] and the glutaredoxin system [12] are
described. In the absence of oxygen the reaction of selenite
terminates after the consumption of 3 molecules of NADPH
consistent with the formation of selenide (Se2−):
SeO23 þ 3NADPHþ Hþ ! Se2 þ 3NADPþ þ 3H2O
GS-Se-SG is also reduced to selenide anaerobically. In
the presence of oxygen, selenide redox cycles with oxygen
leading to a non-stoichiometric consumption of NADPH
[10, 11]. Redox active selenium compounds are effectively
reduced by free cysteine. This reaction may be of particular
importance since a reducing environment, with high
amounts of free thiols, will facilitate selenium uptake [13].
Selenomethylselenocysteine (SeMSeC) is a natural mono-
methylated species found in plants e.g. garlic, onions and
broccoli. The molecule is inert but in the presence of beta-
lyase the highly reactive monomethylselenol (CH3SeH) will
appear [6, 14]. Like selenide monomethylselenol will redox
cycle with oxygen [15]. Monomethylselenol may undergo
methylation to dimethylselenide ((CH3)2Se) or trimethylse-
lenonium ((CH3)3Se
+) or demethylation by demythylase to
selenide [6, 14].
One central role of selenium is the presence of this
element in selenoproteins. There are 25 known selenopro-
teins [16] with diverse functions. In this group several
important redox enzymes are found including the glutathi-
one peroxidase family and thioredoxin reductases [17]. The
synthesis of selenoproteins is complex and the incorpora-
tion of selenocysteine at an exact position within a
selenoprotein follow a unique mechanism [18] requiring
the efficient production of selenide. Physiological as well as
preventive effects of selenium are not solely explained by
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Fig. 1 Cellular mechanisms of selenium on carcinogenesis
Table 1 Sulfur compounds and selenium analogs
Sulfur compound Selenium analog
Inorganic compounds
Hydrogen sulfide (H2S) Hydrogen selenide (H2Se)
Sulfurous acid (H2SO3) Selenious acid (H2SeO3)








Thiol (R-SH) Selenol (R-SeH)
Thiolate (R-S−) Selenolate (R-Se−)
Sulfenic acid (R-SOH) Selenenic acid (R-SeOH)
Sulfinic acid (R-SO2H) Seleninic acid (R-SeO2H)
Sulfonic acid (R-SO3H) Selenonic acid (R-SeO3H)
Sulfoxide (R-SO-R) Selenoxide (R-SeO-R)
Sulfone (R-SO2-R) Selenone (R-SeO2-R)
Disulfide (R-S-S-R) Diselenide (R-Se-Se-R)
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selenoproteins but also by redox modulations and redox
cycles further treated in the following sections. This means
that redox active selenium compounds that are precursors to
selenide and monomethylselenol e.g. selenite, GS-Se-SG
and selenomethylselenocysteine are particularly relevant as
supplements. In Fig. 2 the precursors, key metabolites and
the relation to antitumour effects are summarised.
The fraction of selenide that is not used for seleno-
protein synthesis is either metabolised to selenosugar,
1-Glutathionylseleno-N-acetyl-D-galactosamine and 1-
methylseleno-N-acetyl-D-galactosamine [14, 19] or
methylated to trimethylselenonium prior to excretion [20].
Preventive effects of selenium
Selenium has a long history as a cancer preventive agent.
Several (more than 100) animal studies are reported
supporting cancer preventive effects, but animal studies
are often difficult to translate to humans why this review
focuses on human trials. A few population studies address-
ing total cancer incidence have been published [21–24] and
the results are far clearer with selenium compared to other
so-called antioxidant [25, 26] where many contradictory
data are present. Some of these studies show a correlation
between low serum selenium levels and increased incidence
of mainly breast cancer [27], gastrointestinal cancers [28]
and prostate cancer [29]. The major effects of supplemen-
tation have been observed in the incidences of colorectal-,
lung and prostate cancers along with a drastic decrease in
the total cancer mortality by 50% [21]. There is also a clear
correlation to dose and the base line selenium status of the
study population [30]. In the case of prostate cancer
beneficial effects are clear only in populations with a low
base line selenium level and a low intake [31–33].
Prevention of liver cancer has been observed in endemic
areas of hepatocellular carcinoma and hepatitis in China. In
the studies selenium was supplemented in the table salt
where the study population were given up to 50 micro-
grams daily. The study population was matched to a control
group and after 8 years the incidence of hepatocellular
carcinoma was 35% reduced in the selenium-supplemented
group [34, 35]. A further trial exclusively including patients
with hepatitis B revealed a clear decrease in the incidence
of hepatocellular carcinoma; seven out of 113 patients had
developed HCC in the control group compared to none in
the selenium group [35].
These studies show remarkable effects of selenium in the
prevention of tumours and also clearly demonstrate the
unique properties of selenium compared to other antiox-
idants. As will be discussed below selenium is far from just
an antioxidant and the mechanism of prevention is complex
including both antioxidant, prooxidant and redox regulatory
effects. These important distinctions explain the differences
between selenium and all traditional antioxidants lacking
clear and consequent cancer preventive effects.
There was a great disappointment in the field of
selenium-mediated cancer chemoprevention in 2009 when
the SELECT-trial was closed prior to schedule due to lack
of effects and non-significant increase in the incidence of
prostate cancer in the vitamin E group compared to control
along with a non-significant increase in the incidence of
diabetes type II in the selenium group [36]. The design of
this trial was different compared to previously published
positive trials on three levels; first selenomethionine was
used, second selenium was mixed with high doses of
vitamin E, third the study population was only men with a
high basal level of selenium and a high intake [37]. In
previous studies selenised yeast has been used or inorganic
redox active selenium. Selenised yeast is a mixture of
methylated species where the main fraction is selenome-
thionine [38]. However even other methylated species are
included as exemplified by the highly active selenomethyl-
selenocysteine that is the precursor to monomethylselenol
[20, 38]. This is an important difference that may be a
contributing factor to the disappointing results. Further-
more, vitamin E in high doses might abolish redox effects
by active selenium compounds whereby interfering with the
action of selenium in a negative way (further discussed in
the section below).
The data underline the importance to consider study
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scale prevention study. Furthermore, in order to monitor the
selenium uptake and efficacy of chemical species adminis-
tered, biomarkers shold be considered. By such biomarkers,
the metabolic status could be followed at an individual
level, thereby avoiding false conclusions [39].
Preventive mechanisms of selenium
Selenium compounds can affect carcinogenesis at different
stages of the process (Fig. 1) and vary depending on the
form of selenium administered. The underlying molecular
mechanism is not entirely understood even though several
biochemical/biological processes have been identified [40].
Furthermore, the effects observed occurs at systemic,
cellular and molecular level, including gene expression
and direct protein alterations [14].
Preinitiation effects of selenium
The antioxidant role of selenium is believed to be the most
important preventive effect at very early prenepolastic
onset. The antioxidant effects can in turn be almost directly
attributed to redox active selenoproteins, as selenium
mainly exerts its antioxidant function as a constituent of
selenocystein containing selenoproteins, were selenium
supplementation increases their levels [41]. These proteins
play a central role in upholding the redox homeostasis
within the cell acting as ROS detoxifying agents, and thus
reducing the intracellular environment [42]. In addition to
the reduction of oxygen species they play a crucial role in
reducing intra- and intermolecular disulfides or mixed
disulfides/selenides.
Selenoproteins like thioredoxin reductase and glutathi-
one peroxidase have via their role as redox regulators in the
cell, affecting many biological processes, a most certain
cancer preventive role [33]. However, their role has been
shown to be far more complex as their cytoprotective effects
in established tumours have been shown to turn them into
cancer promoting agents. Apart form acting as cancer
promoting agents, these proteins have also been implicated
in drug resistance for several cytostatic agents [41].
Another important property of selenium in cancer
prevention is its chemical ability to interact with metals,
as several metals have been reported to increase the risk of
cancers [43]. Selenium has been described to interact with
metals like Au, Pt, Cd, Co and Hg etc [43, 44]. Cadmium is
for instance one key element for developing prostate and
breast cancer and selenium have been reported to protect
against cadmium induced peroxidative damage [45]. Sev-
eral of these metals can react and inhibit essential proteins
like thioredoxin reductase, and may thus exert their toxic
effect by modulating the redox balance in the cell.
Selenium in this case acts as a detoxifying agent by
chelating the metal. In a reverse manner metals like copper
have a protective effect against dietary selenium toxicity
[46].
Several genomic approaches have been used to elucidate
the cancer preventing effects of selenium. It is evident from
these studies that selenium can counteract tumour progres-
sion by reversing the expression of genes implicated in
carcinogenesis [47]. Several genes have been identified
including upregulation of genes related to phase II
detoxifying enzymes [48], tumour suppressor genes, select-
ed apoptotic genes including certain caspases. In addition
selenium has been shown to alter the expression of genes
associated to cell cycle regulation in a manner that is
consistent with growth inhibition [49]. Proteomic studies
have also been performed after selenium supplementation
showing clear differences in the abundance of some
proteins [50].
Effects of selenium on carcinogenesis during initiation
and promotion
It is strongly believed that the major effects seen by
selenium compounds in the latter stages of carcinogenesis
can be ascribed to the prooxidative effects of selenium with
redox cycling and ROS production as the main source of
action [51]. The ROS production is a result of redox
cycling of redox active selenium compounds with oxygen,
resulting in a massive non stoichiometric production of
mainly superoxide [52] with an altered and more oxidative
redox balance (Fig. 2), which may eventually lead to cell
death. The redox active selenium metabolites, like selenide,
also cause thiol oxidation (Fig. 3). The oxidation of the
structural cyteine residues leads to a thiol modification,
which directly inhibits several proteins, including signalling
molecules, enzymes, tumour suppressors and transcription
factors. Among these are caspases, p53, AP-1, Sp1, NFkB,

















Fig. 3 Modification of protein thiols by selenium compounds
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proteins is in turn regulated through thiol modification by
thioredoxin [57].
Redox active selenium compounds can all induce
apoptosis, but their mechanism of action differs. Selenide
induces a primarily caspase independent apoptosis generat-
ing DNA strand breaks, activation of p38, induction of p21
and p53. In addition selenide accumulates Bax and down-
regulates Bcl-2. Monomethylselenol on the other hand
induces apoptosis in a caspase dependent manner, upregu-
lating p21 and p16. Furthermore, selenide will cause arrest
in S-phase wile treatment with monomethylselenol results
in G1 arrest. Selenium compounds are also known to
inhibit Erk, AR, Akt, cyclins, and CDKs, thus inhibiting
cell cycle, growth and proliferation [58, 59].
The role of selenium during progression and metastasis
Several studies have shown that selenium compounds
prevent tumour development during the progression phase
of the carcinogenic process [60] and that these effects are
tumour specific [61, 62]. A recent study show that the
tumour specific effect of selenium can be explained by the
extracellular redox environment, where a more reducing
environment (often accounted for by the tumour cells)
favours selenium uptake causing a tumour selective killing
of the cell [13]. In addition selenium treatment can impair
microvascular development [63] and affect the vascular
endothelial growth factor (VEGF) and thereby contributing
to anti-angiogenesis [64]. Through down regulation of
genes such as osteopontin and collagen, selenium also
counteracts metastasis [65, 66]. The tumour specific
toxicity together with the anti-angiogenetic and anti-
metastatic effects of selenium makes it a highly interesting
agent in the arena of chemotherapy.
Concluding remarks
Selenium is unique among the antioxidants and a great
body of evidence clearly show the potential of this element
in large-scale general prevention of human cancers.
Prevention is exerted through several different complex
mechanisms and in all stages of the carcinogenic process.
The chemical properties explain these effects where redox
activity is the key factor. For this reason only redox active
selenium compounds or precursors to these compounds are
the only rational choice in prevention studies.
Future prevention strategies
Selenium compounds are generally cheap and in the correct
dose harmless why selenium supplementation is an attrac-
tive and achievable way to reach decreased cancer
incidences for the benefit of large groups of people
worldwide. If only a fraction of the results indicated in
the positive correctly performed trials could be reached in a
large scale this would have a great impact to reduce
healthcare expenses and human suffering.
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